78
Participants
Start Date
October 19, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
Abrocitinib 200 MG Oral Tablet
Abrocitinib
Ritlecitinib
Ritlecitinib
Placebo
Placebo for Abrocitinib or Ritlecitinib
Royal North Shore Hospital, Saint Leonards
3. Royal Melbourne Hospital, Parkville
The Royal Children's Hospital - Melbourne, Melbourne
Queensland Children's Hospital, South Brisbane
Women and Children's Hospital-Adelaide, Adelaide
Perth Children's Hospital, Nedlands
Columbia University-Naomi Berrie Diabetes Center, New York
Joslin Center at SUNY Upsate, Syracuse
UBMD Pediatrics, Buffalo
University of Pittsburgh, Pittsburgh
Emory Children's Center, Atlanta
University of Florida, Gainesville
University of Miami, Miami
University of South Florida Diabetes Center, Tampa
Vanderbilt University Medical Center, Nashville
University of Louisville Pediatric Endocrinology, Louisville
Indiana University, Indianapolis
University of Minnesota, Minneapolis
University of Chicago, Chicago
The Children's Mercy Hospital, Kansas City
University of Texas Southwestern, Dallas
Barbara Davis Center at University of Colorado Anschutz Medical Campus, Aurora
University of Utah, Salt Lake City
Children's Hospital Orange County, Orange
University of California- San Francisco, San Francisco
Stanford University, Palo Alto
Benaroya Research Institute, Seattle
Yale University School of Medicine, New Haven
Joslin Diabetes Center, Boston
Hospital for Sick Children, Toronto
Collaborators (1)
Pfizer
INDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH